title: Danish guidelines for lipid-lowering treatment in patients with chronic renal failure.
abstract: Measurement of lipid profile in adults with CKD 1-5: We recommend measuring the lipid profile (T cholesterol, LDL cholesterol, HDL cholesterol and triglycerides) in all adults with newly diagnosed CKD 1-5 (including patients in renal replacement therapy). Monitoring of lipid profile in adults with CKD 1-5: In many cases it is not necessary to regularly monitor the lipid profile. Patients ≥ 50 years with CKD 1-5 ND: We recommend that these patients be treated with a statin (CKD 1-2, evidence level B), and in CKD patients in stages 3-5 ND that a statin or the combination statin/ezetimibe be used (evidence level A). Patients aged 18-49 years with CKD 1-5 ND: We suggest treating these patients with a statin if they also have one or more of the following conditions (evidence level A): known CVD, DM, Prior ischaemic stroke, Estimated 10-year risk of coronary death or non-fatal AMI > 10 % or risk of fatal cardiovascular disease > 5% (SCORE). Patients with CKD stage 5D: We suggest that these patients not be given a statin or started on statin/ezetimibe treatment (evidence level A). Patients who start dialysis and are already being treated with a statin or statin/ezetimibe: We suggest that treatment be continued (evidence level C). Adult kidney transplanted patients: We suggest that these patients be treated with a statin (evidence level B).
authors.affiliation: Department of Nephrology, Odense University Hospital, Soendre Boulevard, 5000 Odense, Denmark. hans.dieperink@rsyd.dk.
authors.forename: Hans
authors.initials: H
authors.lastname: Dieperink
authors.forename: Jeppe Hagstrup
authors.initials: JH
authors.lastname: Christensen
authors.forename: Bo
authors.initials: B
authors.lastname: Feldt-Rasmussen
authors.forename: Erik Berg
authors.initials: EB
authors.lastname: Schmidt
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D003718:Denmark; D003925:Diabetic Angiopathies / Q000628:therapy; D003928:Diabetic Nephropathies / Q000628:therapy; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000628:therapy; D016030:Kidney Transplantation; D006435:Renal Dialysis
chemical_list: D000960:Hypolipidemic Agents